Skip to main content

Table 2 Prevalence of components/triads at RS-I-3 within diagnosis of MetS

From: The clinical value of metabolic syndrome and risks of cardiometabolic events and mortality in the elderly: the Rotterdam study

 

AHA/NHLBI

IDF

EGIR

Metabolic Syndrome

3055 (35.3 %)

3646 (42.2 %)

1680 (19.4 %)

Components within diagnosis

BP 2810 (92.0 %)

COB 3646 (100 %)

INS 1680 (100 %)

WC 2319 (75.9 %)

BP 3302 (90.6 %)

WC 1627 (96.8 %)

GLYC 2140 (70.0 %)

GLYC 2489 (68.3 %)

BP 1347 (80.2 %)

HDL 1688 (55.3 %)

HDL 1750 (48.0 %)

DYSL 864 (51.4 %)

TRIG 1849 (60.5 %)

TRIG 1896 (52.0 %)

GLYC 577 (34.3 %)

Triads within diagnosis

GLYC-BP-WC 1469 (48.1 %)

COB-GLYC-BP 2265 (62.1 %)

INS-WC-BP 1302 (77.5 %)

BP-TRIG-WC 1075 (35.2 %)

COB-HDL-BP 1474 (40.4 %)

INS-WC-DYSL 821 (48.9 %)

GLYC-BP-TRIG 1004 (32.9 %)

COB-TRIG-BP 1620 (44.4 %)

INS-BP-DYSL 611 (36.4 %)

BP-HDL-WC 984 (32.2 %)

COB-TRIG-HDL 1074 (29.5 %)

INS-WC-GLYC 549 (32.7 %)

BP-TRIG-HDL 970 (31.8 %)

COB-TRIG-GLYC 1067 (29.3 %)

INS-BP-GLYC 431 (25.7 %)

GLYC-BP-HDL 838 (27.4 %)

COB-HDL-GLYC 926 (25.4 %)

INS-DYSL-GLYC 278 (16.5 %)

GLYC-TRIG-WC 728 (23.8 %)

  

TRIG-HDL-WC 710 (23.2 %)

  

GLYC-HDL-WC 627 (20.5 %)

  

GLYC-TRIG-HDL 633 (20.7 %)

  
  1. AHA/NHLBI, American heart association/national heart, lung, and blood institute; IDF, International Diabetes Federation; EGIR, European Group for the study of Insulin Resistance; GLYC, hyperglycemia; BP, hypertension; TRIG, hypertriglyceridemia; HDL, low HDL-cholesterol; WC, increased waist circumference; COB, central obesity; DYSL dyslipidemia; INS, highest quartile of fasting insulin not having type 2 diabetes